Risteys ·

OMOP concept ID	Test name	Measurement unit (harmonized unit)	N people	N records	Missing measurement value	Harmonized value distribution	Test outcome NA N A AA L LL H HH
3015616	s-ipro	— (—)	496	647	100.00%	Distribution not available
3015616	s-ipro	mmol/l (mmol/l)	46	51	68.63%	Distribution not available

LabWAS

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

Alcohol abuse, main dg, excluding more controls

172

80.00

323.01

1.7

1.0

2.58

—

mmol/l

—

Substance abuse, excluding more controls

388

51.21

307.65

1.4

1.0

2.24

—

mmol/l

—

Mood disorders, excluding more controls

237

18.63

206.19

1.6

1.0

1.99

—

mmol/l

—

Schizophrenia or delusion, excluding more controls

113

33.03

174.97

1.8

1.1

2.06

—

mmol/l

—

Anxiety (asthma-related co-morbidities)

152

20.70

166.24

1.7

1.1

2.31

—

mmol/l

—

Personality disorders, excluding more controls

105

34.03

165.26

2.1

1.0

2.51

—

mmol/l

—

Anxiety disorders, excluding more controls

174

17.15

156.20

1.7

1.0

1.92

—

mmol/l

—

Implicit bacterial Sepsis, including avohilmo

153

105

12.18

138.41

1.3

1.2

1.87

—

mmol/l

—

Bacterial Sepsis

158

114

11.51

137.74

1.3

1.2

1.87

—

mmol/l

—

Implicit bacterial Sepsis

143

101

12.20

131.81

1.3

1.2

1.87

—

mmol/l

—

Accidental poisoning by and exposure to other and unspecified drugs, medicaments and biological substances

27.68

107.41

2.4

1.3

2.34

—

mmol/l

—

Persons encountering health services in other circumstances

118

135

8.68

92.98

1.9

1.1

2.10

—

mmol/l

—

Other anxiety disorders

130

148

7.50

84.86

1.7

1.2

2.01

—

mmol/l

—

Specific personality disorders

104

9.39

81.50

2.0

1.2

2.55

—

mmol/l

—

All anxiety disorders

154

209

5.73

75.67

1.7

1.2

2.31

—

mmol/l

—

Other bacterial diseases

197

281

4.65

72.70

1.3

1.4

1.94

2.56

mmol/l

—

Other bacterial diseases, including avohilmo

202

283

4.46

69.42

1.3

1.4

1.94

2.56

mmol/l

—

Supplementary factors related to causes of morbidity and mortality classified elsewhere

151

6.52

60.54

2.2

1.2

1.60

—

mmol/l

—

Pneumonitis due to solids and liquids

15.82

58.06

1.1

1.3

—

mmol/l

—

Traumatic subdural haemorrhage

16.23

56.56

1.1

1.2

—

mmol/l

—

Other specified and unspecified personality disorders

13.28

48.53

1.7

1.3

3.06

—

mmol/l

—

Lung diseases due to external agents

10.27

45.72

1.1

1.3

—

mmol/l

—

Type of accident

129

5.60

38.30

2.4

1.2

1.60

—

mmol/l

—

Fracture of skull and facial bones

7.46

36.41

1.2

—

mmol/l

—

Panic disorder

9.33

32.66

1.2

1.3

—

Mental and behavioural disorders due to opioids

31.49

30.43

1.2

1.6

—

Dialysis, with operation codes

7.96

28.10

1.3

1.2

—

mmol/l

—

Behavioural syndromes associated with physiological disturbances and physical factors

146

344

2.87

27.96

1.3

1.4

2.05

2.38

mmol/l

—

Sleep disorders

137

339

2.79

25.00

1.2

1.4

2.46

2.38

mmol/l

—

Explicit bacterial Sepsis

9.71

24.98

1.1

1.3

—

Explicit bacterial Sepsis, including avohilmo

9.71

24.98

1.1

1.3

—

Fracture of lower leg, including ankle

293

3.15

23.40

1.8

1.2

2.48

1.72

mmol/l

—

Insomnia

131

342

2.67

22.18

1.2

1.4

2.46

1.98

mmol/l

—

8.51

21.87

1.1

1.2

—

mmol/l

—

Phobic anxiety disorders

7.70

21.58

1.2

1.4

—

mmol/l

—

Dental pulpitis, including avohilmo

139

355

2.51

20.46

1.6

1.2

2.16

2.06

mmol/l

—

Type 2 diabetes, wide definition

105

231

2.87

19.79

1.1

1.2

—

1.24

mmol/l

—

Hypertensive diseases (excluding secondary)

126

3.51

19.14

1.3

—

2.21

mmol/l

—

Early onset COPD, excluding more controls

5.38

18.47

1.3

1.2

—

mmol/l

—

Hernia of abdominal wall, postoperative

6.41

17.72

1.3

1.1

—

Injuries to the wrist and hand

132

382

2.29

16.27

1.8

1.1

1.68

2.52

mmol/l

—

Complications of medical and surgical care

336

2.57

16.24

1.8

1.2

2.40

1.94

mmol/l

—

Hypertension, essential

102

218

2.65

16.17

1.2

—

2.19

mmol/l

—

Hypothyroidism (congenital or acquired)

10.01

15.99

1.2

1.0

—

mmol/l

—

Nontraumatic intracranial haemmorrhage

5.01

15.68

1.0

1.2

—

mmol/l

—

Intracerebral haemorrhage

6.34

14.53

1.0

1.3

—

mmol/l

—

Psychotic depression

36.21

14.43

1.2

1.0

—

mmol/l

—

Nephropathy related operations

5.20

14.36

1.3

—

mmol/l

—

Hypothyroidism, levothyroxine purchases

9.22

14.03

1.2

1.0

—

mmol/l

—

Hypothyroidism and >3 levothyroxin purchases

9.22

14.03

1.2

1.0

—

mmol/l

—

Other symptoms and signs involving general sensations and perceptions

14.83

13.58

1.1

1.7

—

Non-invasive ventilation

18.14

13.46

1.0

—

Hypertensive diseases

226

2.45

13.41

1.3

1.2

—

2.19

mmol/l

—

Hypertension

226

2.45

13.41

1.3

1.2

—

2.19

mmol/l

—

Mental and behavioural disorders due to tobacco

6.08

13.38

1.0

1.3

—

Type 2 diabetes

115

298

2.23

13.02

1.1

1.2

—

1.99

mmol/l

—

Traumatic subarachnoid haemorrhage

24.50

12.47

1.1

1.3

—

mmol/l

—

Injuries to the knee and lower leg

135

363

2.01

11.60

1.7

1.2

1.84

1.72

mmol/l

—

Complications of surgical and medical care, not elsewhere classified

117

376

2.08

11.54

1.6

1.2

2.48

1.72

mmol/l

—

Post-traumatic stress disorder

11.10

11.51

1.2

1.4

—

Smoking dependency

4.92

10.72

1.0

1.3

—

Hard cardiovascular diseases

262

2.19

10.62

1.2

—

1.63

mmol/l

—

Oxycodone

126

3.06

10.51

1.2

1.1

—

mmol/l

—

Speech and linguistic disorders, excluding more controls

20.16

10.31

1.1

1.0

—

Gastric ulcer

4.40

10.24

1.4

1.2

—

Other maltreatment syndromes

13.23

10.17

1.1

1.6

—

Other (not insulin) diabetes medications

108

308

2.06

10.16

1.1

1.2

—

1.52

mmol/l

—

Neurological diseases

210

2.22

10.13

2.1

1.1

1.82

1.80

mmol/l

—

Cardiac arrhythmias

157

2.53

9.57

1.2

1.7

—

2.21

mmol/l

—

Other mental disorders due to brain damage and dysfunction and to physical disease

5.01

9.56

1.5

1.2

—

mmol/l

—

Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified (FINNGEN)

101

2.93

9.45

1.2

1.4

—

1.66

mmol/l

—

Thiamine deficiency

+∞

9.44

1.1

0.0

—

mmol/l

—

Unspecified kidney failure

7.27

9.19

1.3

1.2

—

mmol/l

—

Type 2 diabetes, strict (exclude DM1)

287

2.01

8.77

1.1

1.2

—

1.52

mmol/l

—

Biguanides

104

320

1.96

8.74

1.1

1.2

—

1.58

mmol/l

—

Type 2 diabetes, definitions combined

283

1.99

8.46

1.1

1.2

—

1.53

mmol/l

—

Toxic effect of organic solvents

+∞

8.41

10.1

0.0

—

mmol/l

—

Lower back pain or/and sciatica

119

408

1.81

7.99

1.2

1.3

2.26

1.99

mmol/l

—

Dysphagia

3.38

7.78

1.1

1.2

—

mmol/l

—

Injury of other and unspecified intrathoracic organs

6.37

7.70

1.4

1.3

—

mmol/l

—

Status epilepticus

8.90

7.54

1.1

1.5

—

mmol/l

—

Open wound of ankle and foot

4.09

7.53

1.1

1.2

—

mmol/l

—

Type 2 diabetes, definitions combined, including avohilmo

286

1.92

7.50

1.1

1.2

—

1.53

mmol/l

—

Implicit fungal Sepsis, including avohilmo

7.65

7.38

1.1

1.3

—

Degeneration of nervous system due to alcohol

12.15

7.09

1.7

1.3

—

mmol/l

—

Degeneration of the brain due to alcohol

12.15

7.09

1.7

1.3

—

mmol/l

—

Dissociative [conversion] disorders

12.07

7.08

6.9

1.6

—

Social phobias

5.82

6.90

1.3

1.4

—

mmol/l

—

Focal brain injury

8.27

6.82

1.0

1.2

—

mmol/l

—

Unspecified event, undetermined intent

11.02

6.80

1.1

1.5

—

mmol/l

—

Symptoms and signs involving emotional state

11.00

6.80

1.4

1.9

—

Conduct disorder

16.83

6.75

7.2

1.0

—

Monoamine oxidase A inhibitors

6.42

6.62

1.1

—

mmol/l

—

Gout, strict definition

3.13

6.42

1.1

1.3

—

mmol/l

—

Suppurative and necrotic conditions of lower respiratory tract

6.56

6.33

1.1

1.5

—

Alcoholic gastritis

18.26

6.28

2.3

1.4

—

mmol/l

—

Personal history of certain other diseases

18.17

6.27

1.1

1.0

—

Folate deficiency anaemia

+∞

6.26

1.0

0.0

—

mmol/l

—

COPD-related respiratory insufficiency

3.96

6.16

1.1

1.2

—

Agoraphobia

12.57

6.08

1.0

1.6

—

Open wound of abdomen, lower back and pelvis

8.64

6.06

1.3

1.4

—

mmol/l

—

Other behavioural and emotional disorders with onset usually occurring in childhood and adolescence

6.56

5.93

1.1

1.9

—

Cardiomyopathy

3.00

5.78

1.3

—

mmol/l

—

Injuries involving multiple body regions

6.89

5.74

1.1

1.5

—

Other ill-defined and unspecified causes of mortality

5.18

5.69

1.1

—

mmol/l

—

Gout, idiopatic and unspecified

115

2.61

5.62

1.1

1.2

—

mmol/l

—

Neuromuscular dysfunction of bladder

4.74

5.60

4.6

1.1

—

mmol/l

—

Duodenal ulcer

4.73

5.60

1.2

1.3

—

mmol/l

—

Fall involving bed

12.93

5.58

1.1

—

mmol/l

—

Toxic effect of corrosive substances

+∞

5.23

1.2

0.0

—

mmol/l

—

Oesophageal varices

5.95

5.22

1.1

—

mmol/l

—

Ill-defined and unknown causes of mortality

4.58

5.16

1.1

1.2

—

mmol/l

—

Sequelae of injuries of head

5.21

5.08

1.1

1.4

—

mmol/l

—

Implicit fungal Sepsis

8.38

5.06

1.1

1.6

—

Diffuse brain injury

10.05

5.02

1.1

1.2

—

mmol/l

—

Episodal and paroxysmal disorders

105

324

1.64

4.97

2.0

1.2

1.82

2.30

mmol/l

—

Superficial injuries involving multiple body regions

9.06

4.79

1.1

1.9

—

Pyothorax

6.50

4.77

1.1

1.5

—

Fungal Sepsis

7.18

4.65

1.1

1.5

—

Symptoms and signs concerning food and fluid intake

5.00

4.61

1.0

1.3

—

Visual disturbances and blindness

267

1.91

4.58

1.2

1.5

—

1.64

mmol/l

—

Toxic liver disease

14.14

4.58

1.1

1.0

—

Haemorrhage from respiratory passages

129

2.27

4.53

1.1

—

mmol/l

—

Cirrhosis of liver, NAS

5.24

4.45

1.0

1.1

—

mmol/l

—

COPD, hospital admissions 1, only main diagnosis

127

2.23

4.37

1.3

1.2

—

mmol/l

—

Fracture of neck

4.66

4.36

1.1

1.4

—

mmol/l

—

Any dementia, excluding more controls

3.17

4.34

1.2

1.1

—

mmol/l

—

Other or ill-defined heart diseases

5.02

4.31

1.2

1.5

—

Gout, unspecified

2.56

4.20

1.1

1.2

—

mmol/l

—

Speech disturbances, not elsewhere classified

4.13

4.20

1.1

1.4

—

mmol/l

—

6.92

4.15

1.1

1.5

—

mmol/l

—

Respiratory insufficiency

5.88

4.11

1.1

1.4

—

mmol/l

—

Lesion of ulnar nerve

2.71

4.08

1.1

1.3

—

mmol/l

—

Undetermined asthma, excluding more controls

4.20

4.00

1.1

1.4

—

mmol/l

—

Ischemic heart diseases

281

1.65

4.00

1.2

—

1.98

mmol/l

—

Undetermined asthma

4.06

3.89

1.1

1.3

—

mmol/l

—

Acute gastritis

4.15

3.70

1.0

1.3

—

Mental retardation, excluding more controls

11.61

3.68

1.7

1.0

—

Malignant neoplasm of oral cavity

6.69

3.67

1.0

1.2

—

Unspecified jaundice

6.69

3.67

1.0

1.4

—

mmol/l

—

Cardiomyopathy (excluding other)

2.86

3.62

1.0

1.3

—

mmol/l

—

Hypothyroidism, drug reimbursement

6.98

3.51

1.0

—

Malignant neoplasm of oral cavity, including Hilmo

5.31

3.51

1.0

1.1

—

Vascular diseases of the intestine

6.17

3.50

1.1

1.6

—

Other diseases of pancreas

3.62

3.49

1.2

—

mmol/l

—

Idiopathic gout

3.62

3.49

1.2

1.3

—

Fibrosis and cirrhosis of liver

3.88

3.48

1.0

1.2

—

mmol/l

—

Glomerular disorders in diseases classified elsewhere

2.89

3.46

1.0

1.4

—

mmol/l

—

Thiazolidinediones

3.52

3.39

1.0

1.2

—

Exposure to smoke, fire and flames

7.04

3.36

1.0

1.9

—

Ulcer of lower limb, not elsewhere classified

2.78

3.25

1.0

1.1

—

Lesion of lateral popliteal nerve

4.18

3.19

1.0

1.5

—

mmol/l

—

Special screening examination for infectious and parasitic diseases

2.27

3.12

1.1

1.2

—

Autoimmune diseases excluding thyroid diseases

361

1.47

3.08

1.3

1.4

1.43

2.60

mmol/l

—

Pneumonia derived septicemia

5.02

3.05

1.0

1.6

—

Other respiratory diseases principally affecting the interstitium

2.58

3.04

1.2

—

mmol/l

—

Autoimmune diseases excluding thyroid diseases, strict definition

357

1.46

2.95

1.3

1.4

1.43

2.60

mmol/l

—

Subarachnoid haemorrhage

3.25

2.93

1.1

1.3

—

Barrett oesophagus

4.72

2.92

1.9

1.1

—

mmol/l

—

Myocarditis

4.72

2.91

1.1

—

Peripheral arterial reconstruction

2.69

2.88

1.0

1.2

—

Extreme obesity with alveolar hypoventilation

4.11

2.88

1.1

1.5

—

mmol/l

—

Intestinal malabsorption

4.11

2.88

1.6

1.3

—

mmol/l

—

Oesophagitis

4.10

2.88

1.8

1.1

—

mmol/l

—

Visual impairment including blindness (binocular or monocular)

3.71

2.87

1.3

—

mmol/l

—

Generalized epilepsy, strict definition

6.70

2.87

2.0

1.4

—

Carrier of infectious disease

6.70

2.87

1.3

1.9

—

Acute posthaemorrhagic anaemia

5.40

2.87

1.1

1.5

—

Paralytic ileus

5.40

2.87

1.1

1.5

—

Fibroblastic disorders

2.19

2.82

1.2

—

mmol/l

—

ILD, hospital admissions

2.64

2.79

1.2

—

mmol/l

—

Other interstitial pulmonary diseases

2.64

2.79

1.2

—

mmol/l

—

Interstitial lung disease endpoints

2.64

2.79

1.2

—

mmol/l

—

Interstitial lung disease

2.64

2.79

1.2

—

mmol/l

—

Unknown and unspecified causes of morbidity

3.92

2.77

2.0

1.3

—

Familial hypercholesterolemia

3.08

2.76

1.2

—

mmol/l

—

Somatoform disorder

2.71

1.2

—

mmol/l

—

Neuralgia and neuritis, unspecified

3.76

2.67

1.3

—

Special screening examination for other diseases and disorders

2.86

2.54

1.1

1.2

—

Pneumococcal septicemia

4.39

2.47

1.0

1.8

—

Pacemaker

133

1.89

2.46

1.1

1.2

—

mmol/l

—

Vascular disorders of the intestines

3.81

2.46

1.1

1.3

—

ILD, hospital admission 2, with pulmonary infections

3.13

2.43

1.3

1.2

—

Nonischemic cardiomyopathy

2.90

2.41

1.0

1.3

—

mmol/l

—

Hemiplegia

3.34

2.39

7.3

1.4

—

mmol/l

—

Burns and corrosions of multiple and unspecified body regions

6.28

2.37

1.0

1.3

—

Moderate visual impairment, binocular

6.27

2.37

1.4

1.1

—

mmol/l

—

Diabetic nephropathy, excluding more controls

2.12

2.32

1.0

1.3

—

mmol/l

—

Chronic ulcer of skin, not elsewhere classified

3.22

2.30

1.3

1.1

—

ILD, hospital admissions 3, with pneumonia sepsis

3.22

2.30

1.0

1.3

—

Mumps

4.64

2.27

1.0

1.4

—

Mumps, including avohilmo

4.64

2.27

1.0

1.4

—

Burns and corrosions confined to eye and internal organs

4.63

2.27

1.3

1.4

—

Dermatitis and eczema

427

1.37

2.27

1.3

1.50

2.70

mmol/l

—

Emphysema

3.11

2.22

1.0

1.3

—

mmol/l

—

Unspecified nephritic syndrome

5.58

2.21

1.0

1.2

—

Malignant neoplasm of head and neck

2.86

2.20

1.0

1.1

—

mmol/l

—

Other blood glucose lowering drugs, excl. Insulins

2.41

2.19

1.1

1.4

—

mmol/l

—

Injury of eye and orbit

2.50

2.18

1.2

—

Other orthopaedic follow-up care

3.34

2.18

1.0

1.3

—

Disorder of lipoprotein metabolism, unspecified

2.78

2.13

1.6

1.1

—

Striking against or struck by other objects

220

1.63

2.09

1.4

1.6

—

1.77

mmol/l

—

Schizotypal disorder

5.02

2.07

1.0

1.5

—

Other pulmonary heart/vessel disease

5.01

2.07

1.0

1.4

—

Fentanyl

2.90

2.06

1.1

1.3

—

Rubella [German measles]

3.51

2.05

1.7

1.6

—

mmol/l

—

Rubella [German measles], including avohilmo

3.51

2.05

1.7

1.6

—

mmol/l

—

Residual foreign body in soft tissue

3.08

2.01

1.1

1.3

—

Malignant neoplasm of head and neck, including Hilmo

2.50

2.01

1.0

1.3

—

mmol/l

—

Myalgia

104

1.92

1.99

1.2

1.3

—

Other diseases of intestine

2.15

1.98

1.5

1.3

—

Other arterial embolism and thrombosis

4.56

1.94

1.4

1.3

—

therapeutic use

4.56

1.94

1.0

1.7

—

Bacterial meningitis

4.56

1.94

1.0

1.8

—

Injury of nerves at wrist and hand level

3.76

1.93

1.0

1.1

—

mmol/l

—

Olecranon bursitis

2.97

1.93

1.1

1.6

—

Major coronary heart disease event

298

1.40

1.90

1.2

—

1.98

mmol/l

—

Artificial opening status

3.19

1.88

1.1

—

Arterial embolism and thrombosis

3.19

1.88

1.3

—

Dilated cardiomyopathy

2.31

1.87

1.0

1.3

—

mmol/l

—

Other diseases of stomach and duodenum

2.86

1.86

1.8

1.4

—

Complications of other internal prosthetic devices, implants and grafts

3.54

1.84

1.2

1.4

—

mmol/l

—

Unspecified dementia

3.59

1.84

1.5

1.1

—

Volvulus

4.18

1.82

1.0

1.9

—

mmol/l

—

Haemorrhage, not elsewhere classified

4.18

1.82

1.0

1.7

—

mmol/l

—

Noninfective enteritis and colitis

261

1.53

1.82

1.2

1.5

—

1.75

mmol/l

—

Care involving dialysis

2.76

1.79

1.0

1.2

—

Cluster headache, strict

3.34

1.74

10.5

1.4

—

Cluster headache, wide

3.34

1.74

10.5

1.4

—

Cardiomyopathies, Primary/intrinsic

2.22

1.73

1.0

1.3

—

mmol/l

—

Degenerative diseases of the nervous system

1.80

1.73

1.5

1.1

—

mmol/l

—

Tobacco use

2.67

1.72

1.0

1.4

—

Other diseases of spinal cord

3.86

1.71

1.4

1.5

—

Endocarditis

3.85

1.71

1.2

—

Colectomy operation

2.13

1.71

1.0

1.3

—

Congenital malformations, deformations and chromosomal abnormalities

345

1.43

1.70

1.1

1.4

—

2.21

mmol/l

—

Sulfonylureas

1.79

1.67

1.0

1.2

—

mmol/l

—

Other arrhythmias

240

1.46

1.67

1.1

1.5

—

1.66

mmol/l

—

Essential (haemorrhagic) thrombocythaemia

3.58

1.61

1.0

1.1

—

Simple and mucopurulent chronic bronchitis

3.58

1.61

1.0

1.2

—

mmol/l

—

Alzheimer disease, excluding more controls

3.24

1.60

1.5

1.0

—

Abnormal blood-pressure reading, without diagnosis

3.01

1.58

1.0

1.3

—

Infective dermatitis

2.20

1.56

1.3

1.2

—

mmol/l

—

Spondylopathies

266

1.38

1.56

1.1

1.2

—

1.37

mmol/l

—

Other diseases of oesophagus

2.43

1.53

1.1

1.3

—

mmol/l

—

Disorder of external ear, unspecified

3.34

1.52

3.2

1.7

—

Faecal incontinence

2.60

1.51

1.0

1.2

—

Benign neoplasm: Caecum

0.00

1.51

0.0

1.3

—

Pustulosis palmaris et plantaris

2.86

1.50

1.8

1.4

—

Pruritus

2.22

1.46

1.3

1.2

—

Enlarged lymph nodes

2.22

1.46

1.4

1.2

—

mmol/l

—

Need for other prophylactic measures

2.50

1.45

1.0

1.4

—

Undefined dementia

2.77

1.44

1.5

1.2

—

Other disorders of kidney and ureter

2.12

1.44

1.2

1.3

—

mmol/l

—

Contact with nonpowered hand tool

2.73

1.43

1.0

1.1

—

Other and unspecified injuries of ankle and foot

2.73

1.43

1.2

1.5

—

Plantar fascial fibromatosis

2.31

1.43

1.2

—

mmol/l

—

Ankylosing spondylitis

2.18

1.39

1.2

1.3

—

mmol/l

—

Familial hypercholesterolemia, with ischemic heart disease

2.42

1.39

1.3

1.2

—

mmol/l

—

Malignant neoplasm of eye, brain and central nervous system, including Hilmo

2.42

1.39

1.1

1.2

—

mmol/l

—

Adjustment and management of implanted device

2.08

1.38

1.2

1.1

—

mmol/l

—

Chronic hepatitis, not elsewhere classified

2.95

1.36

1.0

1.4

—

Congenital malformations, deformations and chromosomal abnormalities, including avohilmo

373

1.34

1.31

1.1

1.4

—

2.21

mmol/l

—

Pustular psoriasis

2.50

1.30

1.8

1.4

—

Dementia in Alzheimer disease

2.39

1.30

1.3

1.0

—

Injury of muscle and tendon at wrist and hand level

1.89

1.28

1.0

1.2

—

Other sleep disorders

2.09

1.27

1.4

1.3

—

Perforation of tympanic membrane

2.05

1.26

1.0

1.3

—

mmol/l

—

1.97

1.22

1.0

1.2

—

mmol/l

—

Trochanteric bursitis

2.04

1.22

1.0

1.2

—

Hypogonadotropic hypogonadism

2.64

1.21

1.0

1.2

—

Diseases of veins, lymphatic vessels and lymph nodes, not elsewhere classified

377

1.27

1.20

1.1

1.2

—

1.81

mmol/l

—

Panniculitis affecting regions of neck and back

2.50

1.15

1.0

1.3

—

Hypercalcemia

2.50

1.15

1.0

1.5

—

Other symptoms and signs involving the digestive system and abdomen

1.96

1.11

1.2

—

mmol/l

—

Other and unspecified abdominal hernia

2.38

1.09

1.0

1.5

—

Malignant neoplasm of brain, including Hilmo

2.38

1.09

1.2

—

mmol/l

—

Right hemicolectomy

2.38

1.09

1.0

1.5

—

Macular hole

2.28

1.03

1.0

1.4

—

Dementia

104

1.51

1.03

1.2

1.1

—

mmol/l

—

Viral pneumonia (unknown virus, not influenza)

2.06

1.03

1.0

1.3

—

Cyst of kidney

2.00

1.00

1.3

—

mmol/l

—

Other infectious diseases

2.00

1.00

1.1

1.3

—

Unspecified urinary incontinence

2.00

1.00

1.0

1.3

—

Orchitis and epididymitis

1.84

0.98

1.1

1.3

—

Follow-up examination after treatment for malignant neoplasms

2.18

0.98

1.0

1.2

—

mmol/l

—

Other specified cerebrovascular diseases, other cerebrovascular disorders in diseases classified elsewhere

2.17

0.98

1.4

1.5

—

Benign neoplasm: Cerebral meninges

1.95

0.97

1.0

1.3

—

mmol/l

—

ILD, hospital admissions 1, main diag only

1.73

0.92

1.0

1.2

—

mmol/l

—

Intermittent heterotropia

2.14

0.91

1.2

1.4

—

Extracorporeal dialysis

2.07

0.89

1.0

1.4

—

Endovascular or surgical operations to intracerebral aneurysms

2.07

0.89

1.0

1.4

—

Malignant neoplasm of bladder, including Hilmo

1.93

0.89

1.0

1.1

—

mmol/l

—

Myeloproliferative diseases (CML excluded)

2.00

0.87

1.0

1.3

—

Abnormal spermatozoa

1.72

0.86

1.1

1.3

—

Any dementia

1.49

0.86

1.2

1.1

—

mmol/l

—

Statin medication

231

1.27

0.84

1.2

1.3

—

2.34

mmol/l

—

Pneumothorax

1.94

0.84

1.2

1.4

—

Vitreous haemorrhage

1.78

0.84

1.0

1.2

—

Ganglion

1.59

0.84

1.1

1.9

—

Percutaneous Coronary Intervention

272

1.25

0.83

1.2

—

1.98

mmol/l

—

Polyarthropathies

271

1.26

0.82

1.2

1.5

—

1.89

mmol/l

—

Peripheral artery operations in Hilmo

1.74

0.82

1.0

1.3

—

Synovial cyst of popliteal space [Baker]

1.88

0.81

1.0

1.3

—

mmol/l

—

Other arthrosis

219

1.28

0.79

1.1

1.2

—

1.94

mmol/l

—

Melanocytic naevi of lower limb, including hip

0.00

0.79

0.0

1.4

—

Inflammatory disease of cervix uteri

0.00

0.79

0.0

1.3

—

Amputation

1.82

0.79

1.0

1.3

—

Adhesive capsulitis of shoulder

1.67

0.78

1.2

1.3

—

Benign neoplasm: Connective and other soft tissue of upper limb, including shoulder

0.00

0.78

0.0

1.3

—

Non-allergic asthma (mode), excluding more controls

1.65

0.77

1.0

1.3

—

mmol/l

—

Ankylosing spondylitis, strict definition

2.09

0.74

1.4

—

Meningitis

2.00

0.72

1.0

1.4

—

Nummular dermatitis

1.80

0.72

1.0

1.2

—

mmol/l

—

Coronary revascularization (ANGIO or CABG)

272

1.23

0.72

1.2

—

1.98

mmol/l

—

Chronic laryngitis and laryngotracheitis

1.61

0.72

1.1

—

Pleural effusion

1.67

0.72

1.1

1.2

—

Palmar fascial fibromatosis [Dupuytren]

1.62

0.71

1.3

—

mmol/l

—

Dementia, including avohilmo

125

1.36

0.71

1.2

1.1

—

mmol/l

—

Transplanted organ and tissue status

1.75

0.71

1.0

1.3

—

Other symptoms and signs involving the circulatory and respiratory systems

1.92

0.70

2.4

1.2

—

Amiodarone users

1.71

0.70

1.1

1.2

—

Other hammer toe(s) (acquired)

1.65

0.69

1.0

1.1

—

mmol/l

—

Contusion of other and unspecified parts of foot

1.85

0.68

1.0

1.4

—

Oral leukoplakia and other epithelial disorders of tongue and oral cavity , including avohilmo

1.67

0.68

1.0

1.3

—

Other disorders of penis

1.64

0.68

1.0

1.3

—

mmol/l

—

Other inflammation of eyelid, including avohilmo

273

0.73

0.67

1.1

1.5

—

1.76

—

Artrosis, including avohilmo

316

0.81

0.67

1.3

1.2

—

2.17

mmol/l

—

Colorectal cancer

101

0.57

0.61

1.2

—

conjunctival haemorrhage

1.67

0.61

2.2

1.2

—

L02BB Anti-androgens

1.67

0.61

1.0

1.2

—

Malignant neoplasm of ovary, including Hilmo

0.00

0.60

0.0

1.2

—

Non-allergic asthma (mode)

1.55

0.60

1.0

1.3

—

mmol/l

—

Other specified and unspecified retinal disorders

0.00

0.59

0.0

1.5

—

Use of antiglaucoma preparations and miotics

0.00

0.58

0.0

1.5

—

Benign neoplasm of brain and other parts of central nervous system

1.72

0.57

1.2

1.3

—

mmol/l

—

Myeloproliferative diseases

1.72

0.57

1.0

1.3

—

Actinic keratosis

136

0.67

0.57

1.0

1.2

—

mmol/l

—

Colorectal adenocarcinoma

0.57

0.56

1.0

1.2

—

Hypothyroidism, strict autoimmune, 3 medication purchases required

300

1.19

0.54

1.1

1.4

—

1.62

mmol/l

—

Diabetic neuropathy

1.46

0.53

1.0

1.3

—

Metatarsalgia

1.54

0.53

1.0

1.2

—

Bronchitis, not specified as acute or chronic

1.50

0.51

1.0

1.2

—

Cerebral aneurysm, nonruptured

1.46

0.50

1.0

1.3

—

AV-block

1.50

0.49

1.0

1.2

—

mmol/l

—

Skin changes due to chronic exposure to nonionizing radiation

141

0.71

0.49

1.0

1.2

—

mmol/l

—

150

0.72

0.48

1.0

1.2

—

mmol/l

—

Cholecystitis

1.46

0.46

1.0

1.2

—

mmol/l

—

Primary coxarthrosis, bilateral

120

1.33

0.46

1.1

1.2

—

mmol/l

—

1.38

0.44

1.0

1.1

—

mmol/l

—

Hypothyreosis and Thyroxine purchase for inclusion criteria

337

1.15

0.43

1.1

1.4

—

1.53

mmol/l

—

Cardiomyopathy, other and unspecified

1.61

0.43

2.2

1.4

—

Unspecified misadventure during surgical and medical care

1.56

0.42

12.4

1.3

—

mmol/l

—

Chronic suppurative otitis media

1.56

0.42

1.2

1.3

—

Benign neoplasm: Ascending colon

1.38

0.41

1.1

1.2

—

Other disorders of nervous system

1.52

0.41

1.2

—

Other specific arthropathies, wide

0.00

0.41

0.0

1.7

—

IgA nephropathy (IgA glomerulonephritis)

0.00

0.41

0.0

1.5

—

Other articular cartilage disorders

0.00

0.41

0.0

1.5

—

Oral leukoplakia, including avohilmo

0.00

0.41

0.0

1.2

—

Systemic lupus erythematosus, unspecified

0.00

0.41

0.0

1.5

—

Use of ropinirole

0.00

0.41

0.0

1.2

—

SLE, ICD10

0.00

0.41

0.0

1.5

—

SLE, strict definition

0.00

0.41

0.0

1.5

—

Cystic kidney disease, including avohilmo

0.00

0.41

0.0

1.8

—

Systemic lupus erythematosus

0.00

0.41

0.0

1.5

—

Use of rivastigmine

1.51

0.41

1.6

1.1

—

Chondromalacia

0.00

0.41

0.0

1.6

—

Other acute skin changes due to ultraviolet radiation

0.00

0.41

0.0

1.4

—

Malignant neoplasm of mesothelium and soft tissue

0.00

0.41

0.0

1.2

—

Malignant neoplasm of ovary

0.00

0.41

0.0

1.2

—

Other benign neoplasms of uterus

0.00

0.41

0.0

1.5

—

Other dialysis

0.00

0.40

0.0

1.2

—

Other and unspecified disorders involving the immune mechanism, not elsewhere classified

0.00

0.40

0.0

1.5

—

Other disorders involving the immune mechanism, not elsewhere classified

0.00

0.40

0.0

1.5

—

Ulcerative enterocolitis

0.00

0.40

0.0

1.2

—

Melanoma in situ

0.00

0.40

0.0

1.2

—

Glaucoma-related operations

0.00

0.40

0.0

1.5

—

Other diseases of blood and blood-forming organs

1.47

0.40

1.0

1.3

—

mmol/l

—

Other noninflammatory disorders of vulva and perineum

1.47

0.40

1.4

1.0

—

mmol/l

—

Meralgia paraesthetica

0.00

0.40

0.0

1.6

—

Multiple myeloma and malignant plasma cell neoplasms

0.00

0.40

0.0

1.4

—

Female infertility, tubal origin

0.00

0.40

0.0

1.1

—

Valvular operations

1.31

0.39

1.3

—

mmol/l

—

Twin gestation

1.43

0.39

2.0

1.2

—

Peripheral retinal degeneration

0.00

0.39

0.0

1.6

—

Bicuspidal aortic valve syndrome

0.00

0.39

0.0

1.3

—

Medial epicondylitis

0.00

0.39

0.0

1.4

—

Other noninflammatory disorders of cervix uteri

0.00

0.39

0.0

1.1

—

Hypothyroidism, other/unspecified

336

1.13

0.38

1.1

1.4

—

1.53

mmol/l

—

Alzheimer disease, including avohilmo

0.70

0.38

1.4

1.1

—

Disorders of tooth development and eruption

1.40

0.37

1.1

—

mmol/l

—

Malignant neoplasm of urinary organs

1.35

0.37

1.0

1.1

—

Other pleural conditions

1.35

0.37

1.0

1.3

—

Varicose veins

227

0.83

0.36

1.0

1.2

—

2.20

—

Myocardial infarction, with ST-elevation

1.27

0.36

1.1

1.3

—

Other enthesopathy of foot (+metatarsalgia)

1.40

0.35

1.0

1.2

—

Disorders of vitreous body and globe

249

0.83

0.32

1.0

1.2

—

1.71

—

Emergency coronary revascularization (for ACS)

313

1.12

0.32

1.2

—

1.98

mmol/l

—

Alzheimer disease

0.72

0.31

1.4

1.1

—

Lung cancer and mesothelioma

1.30

0.28

1.4

1.3

—

mmol/l

—

Lateral epicondylitis

1.25

0.27

1.1

1.3

—

Aortic aneurysm

114

0.77

0.27

1.0

1.2

—

mmol/l

—

Malignant neoplasm of bronchus and lung

1.22

0.27

1.4

1.2

—

mmol/l

—

Use of other anti-dementia drugs

1.21

0.27

1.1

—

Use of memantine

1.21

0.27

1.1

—

Disorders of vitreous body

243

0.86

0.24

1.0

1.2

—

1.83

—

Other diseases of arteries and capillaries

1.28

0.23

1.2

1.3

—

Benign neoplasm: Skin of other and unspecified parts of face

1.28

0.23

1.0

1.3

—

Reimbursement for rheumatic diseases

304

0.88

0.22

1.1

1.4

—

1.98

mmol/l

—

Benign neoplasm of major salivary glands

1.22

0.22

1.0

1.3

—

Nail disorders

1.19

0.21

1.2

1.3

—

Malignant neoplasm of urinary organs, including Hilmo

1.19

0.21

1.0

1.1

—

Other disorders of breast and lactation associated with childbirth

0.00

0.21

0.0

1.3

—

Cardiomyopathy, Hypertrophic obstructive

0.00

0.21

0.0

1.3

—

Other specified/unspecified deforming dorsopathies

0.00

0.21

0.0

1.5

—

Venous complications and haemorrhoids in pregnancy

0.00

0.21

0.0

1.7

—

Complications associated with artificial fertilization

0.00

0.21

0.0

1.0

—

Sexual dysfunction

0.00

0.21

0.0

1.4

—

Primary biliary cholangitis (PBC)

0.00

0.21

0.0

1.5

—

Epiphora

0.00

0.21

0.0

1.4

—

Habitual aborter

0.00

0.21

0.0

1.0

—

Graves ophthalmopathy

0.00

0.21

0.0

1.5

—

Other and unspecified nail disorders

0.00

0.21

0.0

1.6

—

Polycystic kidney disease

0.00

0.21

0.0

1.8

—

Other specified/unspecified spondylopathies

0.00

0.21

0.0

1.1

—

Granulomatous disorders of skin and subcutaneous tissue

0.00

0.21

0.0

1.0

—

Rare circulating lymphoid malignancy, including Hilmo

0.00

0.21

0.0

1.3

—

Use of levodopa decarbox-comt-inhibitor

0.00

0.21

0.0

1.3

—

Pneumonia due to other infectious organisms, not elsewhere classified

0.00

0.21

0.0

1.9

—

Adenocarcinoma and ductal carcinoma of pancreas

0.00

0.21

0.0

1.2

—

Benign neoplasm: Skin of ear and external auricular canal

0.00

0.21

0.0

1.5

—

Other assisted single delivery

0.00

0.21

0.0

1.7

—

Cytomegalovirus infection, IBD co-morbidity

0.00

0.21

0.0

1.8

—

Cytomegaloviral disease

0.00

0.21

0.0

1.7

—

Cytomegaloviral disease, including avohilmo

0.00

0.21

0.0

1.7

—

Chronic Coagulation defects

0.00

0.21

0.0

1.7

—

Disorders of lacrimal system and orbit in diseases classified elsewhere

0.00

0.21

0.0

1.4

—

Torsion of ovary, ovarian pedicle and fallopian tube

0.00

0.21

0.0

1.0

—

Other and unspecified mononeuropathies of lower limb

0.00

0.21

0.0

1.5

—

Hodgkin lymphoma, hilmo

0.00

0.21

0.0

1.5

—

Congenital iodine-deficiency syndrome/hypothyroidism

0.00

0.21

0.0

1.7

—

Macular cyst

0.00

0.21

0.0

1.1

—

Certain zoonotic bacterial diseases, including avohilmo

0.00

0.21

0.0

1.7

—

Serous carcinoma of ovary, including Hilmo

0.00

0.21

0.0

1.0

—

Dissection of aorta

0.00

0.21

0.0

1.2

—

Non-small cell lung cancer, squamous, helper endpoint

0.00

0.21

0.0

1.2

—

Polymyalgia rheumatica

1.16

0.21

1.0

1.2

—

Bruxism

0.00

0.21

0.0

1.6

—

Hyperaldosteronism

0.00

0.21

0.0

1.4

—

Cystic kidney disease

0.00

0.21

0.0

1.7

—

Multiple myeloma, including Hilmo

0.00

0.21

0.0

1.2

—

Inflammatory diseases of prostate (prostatitis)

1.24

0.20

1.3

1.2

—

Disorders of eyelid, lacrimal system and orbit

375

0.92

0.20

1.0

1.4

—

1.79

mmol/l

—

Idiopathic urticaria

0.00

0.20

0.0

1.4

—

Keratoconus

0.00

0.20

0.0

1.4

—

Erosion and ectropion of cervix uteri

0.00

0.20

0.0

1.0

—

Protozoal diseases

0.00

0.20

0.0

1.6

—

Protozoal diseases, including avohilmo

0.00

0.20

0.0

1.6

—

Nontoxic diffuse goitre

0.00

0.20

0.0

1.6

—

Subacute thyroiditis

0.00

0.20

0.0

1.6

—

Use of selegiline

0.00

0.20

0.0

1.2

—

Respiratory tuberculosis, confirmed and not-confirmed

0.00

0.20

0.0

1.2

—

Respiratory tuberculosis

0.00

0.20

0.0

1.2

—

Tuberculosis

0.00

0.20

0.0

1.2

—

Disorders of breast

169

1.15

0.20

1.2

1.6

—

1.92

—

Other disorders of conjunctiva

1.18

0.19

2.0

1.2

—

Disorders of lacrimal system

212

1.11

0.16

1.0

1.5

—

1.92

mmol/l

—

Disorders of the thyroid gland

373

0.94

0.15

1.1

1.4

—

1.59

mmol/l

—

L04AX Other immunosuppressants

327

0.92

0.15

1.0

1.4

—

1.67

mmol/l

—

Malignant neoplasm of respiratory system and intrathoracic organs

1.20

0.14

1.3

1.2

—

mmol/l

—

Haemorrhoids and perianal venous thrombosis

157

0.89

0.12

1.1

1.2

—

mmol/l

—

Benign neoplasm: Transverse colon

1.14

0.10

1.4

1.3

—

mmol/l

—

Benign leiomyoma with endometriosis

1.11

0.09

1.0

1.2

—

mmol/l

—

Postpartum care and examination

1.05

0.08

1.3

1.5

—

Gonarthrosis

226

1.05

0.08

1.2

—

1.94

mmol/l

—

Secondary malignant neoplasm of respiratory and digestive organs, including Hilmo

0.86

0.07

1.0

1.2

—

Benign neoplasm: Sigmoid colon

0.83

0.07

1.1

1.3

—

Malignant neoplasm of respiratory system and intrathoracic organs, including Hilmo

1.12

0.07

1.3

1.2

—

mmol/l

—

Nasal polyp

100

0.90

0.06

1.0

1.2

—

mmol/l

—

ILD medications: immunosuppressive drugs

376

0.96

0.05

1.1

1.2

—

2.19

mmol/l

—

Use of anticholinesterases

0.92

0.03

1.4

1.0

—

N06DA Anticholinesterases

0.92

0.03

1.4

1.0

—

Arthrosis

253

0.97

0.03

1.2

—

1.87

mmol/l

—

Disorders of sclera, cornea, iris and ciliary body

326

0.98

0.00

1.5

1.4

—

1.67

mmol/l

—

Second line medication for Crohn's disease

337

1.01

0.00

1.0

1.4

—

1.65

mmol/l

—

Unspecific neurodegenerative disorder

1.04

0.00

1.3

1.1

—

Other enthesopathies

142

0.99

0.00

1.1

1.2

—

Normal-pressure hydrocephalus

0.00

0.0

1.3

—

Malignant neoplasm of other and unspecified female genital organs

0.00

0.0

1.0

—

Retinoschisis and retinal cysts

0.00

0.0

1.4

—

Non-small cell lung cancer, including Hilmo

0.92

0.00

1.4

1.1

—

mmol/l

—

Crushing injury of wrist and hand

0.00

0.0

1.5

—

Abnormal findings on diagnostic imaging of breast

0.00

0.0

1.0

—

Use of cabergoline

0.00

0.0

1.0

—

Use of rasagiline

0.00

0.0

1.3

—

Achilles tendinitis

0.91

0.00

1.6

1.3

—

Arthropathy in ulcerative colitis

0.00

0.0

1.5

—

Other melanin hyperpigmentation

0.00

0.0

1.0

—

Granuloma annulare

0.00

0.0

1.0

—

Non-small cell lung cancer, squamous

0.00

0.0

1.2

—

Other benign neoplasm of uterus: Other parts/unspecified

0.00

0.0

1.0

—

Malignant neoplasm of other and unspecified female genital organs, including Hilmo

0.00

0.0

1.0

—

Malignant neoplasm of bone and articular cartilage

0.00

0.0

1.6

—

Malignant neoplasm of other connective and soft tissue

0.00

0.0

1.3

—

Pneumocystosis

0.00

0.0

1.6

—

Pneumocystosis, including avohilmo

0.00

0.0

1.6

—

Other/unspecified cytomegaloviral diseases

0.00

0.0

1.9

—

Other retinal artery occlusion

0.00

0.0

1.3

—

Urethritis and urethral syndrome

0.00

0.0

1.0

—

Other lesions of median nerve

0.00

-0.00

0.0

1.6

—

Parkinson's disease, including avohilmo

0.89

-0.00

1.2

—

mmol/l

—

Third [oculomotor] nerve palsy

0.00

-0.00

0.0

2.0

—

Endometriosis of fallopian tube

0.00

-0.00

0.0

1.0

—

Endometriosis of intestine

0.00

-0.00

0.0

1.0

—

Endometriosis of ovary

1.00

-0.00

1.4

1.1

—

mmol/l

—

Hyphaema and other vascular disorders of iris and ciliary body

0.00

-0.00

0.0

1.2

—

Other disorders of iris and ciliary body

0.00

-0.00

0.0

1.1

—

Early lumbar disc prolapse, operated

0.85

-0.00

1.2

1.3

—

mmol/l

—

Respiratory conditions due to other external agents

0.00

-0.00

0.0

1.2

—

Androgenic alopecia

0.00

-0.00

0.0

1.6

—

Abscess of external ear

0.00

-0.00

0.0

1.0

—

Hereditary retinal dystrophy

0.00

-0.00

0.0

1.1

—

Thoracic aortic aneurysm

0.99

-0.00

1.0

1.3

—

mmol/l

—

Other and unspecified acute skin changes due to ultraviolet radiation

0.00

-0.00

0.0

1.3

—

CR(E)ST syndrome

0.00

-0.00

0.0

1.8

—

Melanocytic naevi of scalp and neck

0.00

-0.00

0.0

2.3

—

Diseases of spleen

0.00

-0.00

0.0

1.0

—

Pleural plaque without asbestos

0.00

-0.00

0.0

1.4

—

Adenocarcinoma of pancreas

0.00

-0.00

0.0

1.3

—

Non-Hodgkin lymphoma, all

0.00

-0.00

0.0

1.2

—

Xerosis cutis

0.00

-0.00

0.0

1.0

—

Secondary malignant neoplasm of respiratory and digestive organs

0.00

-0.00

0.0

1.4

—

Benign neoplasm: Anus and anal canal

0.00

-0.00

0.0

1.1

—

Parapsoriasis

0.00

-0.00

0.0

1.0

—

Corneal degeneration

0.00

-0.00

0.0

1.3

—

Calcaneal spur

0.00

-0.00

0.0

2.0

—

Morphin

0.00

-0.00

0.0

1.2

—

Multiple myeloma

0.00

-0.00

0.0

1.3

—

Benign neoplasm: Rectum

0.90

-0.00

1.1

1.2

—

Iliotibial band syndrome

0.00

-0.00

0.0

1.7

—

Carcinoma in situ of cervix uteri, endocervix

0.00

-0.00

0.0

1.9

—

Benign neoplasm: Vagina

0.00

-0.00

0.0

2.3

—

Use of fingolimod

0.00

-0.00

0.0

1.5

—

Carcinoma in situ of skin of upper limb, including shoulder

0.00

-0.00

0.0

1.4

—

Fistulae involving female genital tract

0.00

-0.00

0.0

1.0

—

Acute otitis externa, noninfective

0.00

-0.00

0.0

1.4

—

Carcinoma in situ of breast, other/unspecified

0.00

-0.00

0.0

1.0

—

Other protozoal intestinal diseases, including avohilmo

0.00

-0.00

0.0

1.6

—

Migraine without aura, drug-induced

0.00

-0.00

0.0

1.5

—

Myeloid leukaemia

0.00

-0.00

0.0

1.4

—

Injury of muscle and tendon at lower leg level

0.98

-0.00

1.0

1.2

—

Viral infections of central nervous system, not elsewhere classified/unspecifie, including avohilmod

0.00

-0.00

0.0

2.0

—

Use of teriflunomide

0.00

-0.00

0.0

1.5

—

Other specified congenital malformation syndromes affecting multiple systems

0.00

-0.00

0.0

1.6

—

Tularaemia, including avohilmo

0.00

-0.00

0.0

1.4

—

Prolapse and hernia of ovary and fallopian tube

0.00

-0.00

0.0

1.0

—

Von Willebrand disease

0.00

-0.00

0.0

1.5

—

Other abortion

0.00

-0.00

0.0

2.6

—

Inflammatory disorders of male genital organs, not elsewhere classified

0.00

-0.00

0.0

1.3

—

Placental disorders

0.00

-0.00

0.0

1.5

—

Hydatidiform mole

0.00

-0.00

0.0

2.3

—

Malignant neoplasm of bronchus and lung, including Hilmo

0.93

-0.00

1.4

1.2

—

mmol/l

—

Infliximab

0.00

-0.00

0.0

1.4

—

Allergic contact dermatitis due to drugs in contact with skin

0.00

-0.00

0.0

1.4

—

Brain glioblastoma

0.00

-0.00

0.0

1.3

—

Other mycoses, not elsewhere classified/unspecified, including avohilmo

0.00

-0.00

0.0

1.2

—

Malignant neoplasm of other and unspecified parts of biliary tract, including Hilmo

0.00

-0.00

0.0

1.4

—

Other abnormal immunological findings in serum

0.00

-0.00

0.0

1.6

—

Multiple myeloma, Monoclonal gammopathy of undetermined significance (MGUS)

0.00

-0.00

0.0

1.3

—

Benign neoplasm: Rectum, anus and anal canal

0.98

-0.00

1.3

1.2

—

Marginal zone B-cell lymphoma, including Hilmo

0.00

-0.00

0.0

1.4

—

Venous complications and haemorrhoids in the puerperium

0.00

-0.00

0.0

1.0

—

Contact with other hot metals

0.00

-0.00

0.0

1.6

—

Occupant of special all-terrain or other motor vehicle designed primarily for off-road use, injured in transport accident

0.00

-0.00

0.0

1.1

—

Exposure to other and unspecified man-made environmental factors

0.00

-0.00

0.0

1.1

—

Family history of other conditions

0.00

-0.00

0.0

1.0

—

0.00

-0.00

0.0

1.7

—

Liveborn infants according to place of birth

0.00

-0.00

0.0

1.0

—

Disorders of globe

0.00

-0.00

0.0

1.3

—

Drug-induced osteoporosis

0.00

-0.00

0.0

1.8

—

Family history of other specific disorders

0.00

-0.00

0.0

1.0

—

Benign neoplasm: Skin of scalp and neck

0.00

-0.00

0.0

2.0

—

Problems related to social environment

0.00

-0.00

0.0

2.0

—

Viral infections of central nervous system, not elsewhere classified/unspecified

0.00

-0.00

0.0

2.0

—

Respiratory tuberculosis, not confirmed

0.00

-0.00

0.0

1.4

—

Other immunodeficiencies

0.00

-0.00

0.0

1.7

—

Female infertility, uterine origin

0.00

-0.00

0.0

1.0

—

Background retinopathy and retinal vascular changes

0.00

-0.00

0.0

1.7

—

Other abnormal auditory perceptions

0.00

-0.00

0.0

2.2

—

Vertigo of central origin

0.00

-0.00

0.0

1.6

—

Pterygium

0.00

-0.00

0.0

1.4

—

Panhypopituitarism

0.00

-0.00

0.0

1.3

—

Eosinophilic disease (BM)

0.00

-0.00

0.0

1.7

—

Dementia due to Parkinson's disease

0.00

-0.00

0.0

1.4

—

Graves ophthalmopathy, strict

0.00

-0.00

0.0

1.6

—

Mixed connective tissue disease

0.00

-0.00

0.0

1.5

—

Thyroiditis, unspecified

0.00

-0.00

0.0

2.3

—

Other acute disseminated demyelination

0.00

-0.00

0.0

1.5

—

Benign neoplasm: Lip

0.00

-0.00

0.0

1.7

—

Respiratory tuberculosis, not confirmed, including avohilmo

0.00

-0.00

0.0

1.4

—

Other and unspecified acne

0.00

-0.00

0.0

1.0

—

≡ Risteys

R14

FinnGen R13 + FinRegistry

FinnGen R12 + FinRegistry

FinnGen R11 + FinRegistry

FinnGen R10 + FinRegistry

FinnGen R10

FinnGen R9

FinnGen R8

FinnGen R7

FinnGen R6

FinnGen R5

FinnGen R4

FinnGen R3

Isopropanol [Moles/volume] in Serum or Plasma

Coding

Definition

OMOP mapping QC

Cohort

Year of birth distribution

Age at first measurement

Age at last measurement

Age at start of registry

Duration from first to last measurement

Statistics

Number of measurements over the years

Number of measurements per person

Distribution of lab values

Value range per person

LabWAS